Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519447 | 1.00 | KMT2A (0.46) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30795242 | 1.00 | KMT2A (0.46) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4526768 | 1.00 | KMT2A (0.46) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30824681 | 1.00 | KMT2A (0.46) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4527601 | 0.93 | KMT2A (0.54) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30795072 | 0.93 | GPR139 (0.47) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30796606 | 0.93 | KMT2A (0.54) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4516864 | 0.93 | GPR139 (0.47) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30795026 | 0.92 | GPR139 (0.45) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4503557 | 0.92 | GPR139 (0.45) | KMT2ACYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291973-A1 | Novel Quinazoline Derivatives and Their Medical Use | KCNA7, KCNN3, KCNQ5 | KMT2A 1926/4885CYP1A2 1184/4885CYP3A4 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.